It is too early to say whether the 47% efficacy shown in interim results of the Phase IIb/III HERALD study of CureVac NV’s COVID-19 vaccine candidate will be sufficient to recommend it for EU marketing authorization, according to the European Medicines Agency.
The vaccine is currently undergoing a rolling review in the EU, whereby data are being submitted as they are generated,...